Deciphera Pharmaceuticals, Inc.
DCPHDrugs in Pipeline
9
Phase 3 Programs
6
Upcoming Catalysts
3
Next Catalyst
Mar 2027
Market Overview
Stock performance and key metrics
4 upcoming, 0 past
Ripretinib
GIST
Vimseltinib
Chronic Graft-Versus-Host Disease (cGVHD)
DCC-2618
Gastrointestinal Stromal Tumors
Sapablursen
Polycythemia Vera
Tirabrutinib
Relapsed/Refractory Primary Central Nervous System Lymphoma
Sunitinib
Gastrointestinal Stromal Tumors
DCC-3084
Advanced Solid Tumor
DCC-3009
Gastrointestinal Stromal Tumor (GIST)
Inlexisertib
Non-Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ripretinib | Phase 3 | GIST | - | - |
Vimseltinib | Phase 3 | Chronic Graft-Versus-Host Disease (cGVHD) | - | - |
DCC-2618 | Phase 3 | Gastrointestinal Stromal Tumors | - | - |
Sapablursen | Phase 3 | Polycythemia Vera | - | - |
Tirabrutinib | Phase 3 | Relapsed/Refractory Primary Central Nervous System Lymphoma | - | - |
Sunitinib | Phase 3 | Gastrointestinal Stromal Tumors | - | - |
DCC-3084 | Phase 2 | Advanced Solid Tumor | - | - |
DCC-3009 | Phase 2 | Gastrointestinal Stromal Tumor (GIST) | - | - |
Inlexisertib | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Deciphera Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 9 drug candidates in Deciphera Pharmaceuticals, Inc.'s (DCPH) pipeline across Phase 3, Phase 2. Its lead program is Ripretinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Deciphera Pharmaceuticals, Inc.'s next FDA catalyst?→
Deciphera Pharmaceuticals, Inc.'s (DCPH) next tracked catalyst is a Phase 2 expected March 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DCPH biotech catalysts?→
Add DCPH to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Deciphera Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.